🇺🇸

US SEC Filing Intelligence

· daily

Dow Jones 30 Stocks SEC Filings — September 24, 2026

The 16 filings for September 24, 2026, present a starkly contrasting picture of insider activity within the Dow Jones 30. The dominant theme is a wave of routine, non-cash equity awards to directors and executives at **UnitedHealth Group (UNH)**, involving 15 separate filings. These are standard compensation events with no market-moving implications, reflecting a neutral sentiment and low materiality. In sharp contrast, a single filing from **Apple Inc. (AAPL)** reveals a significant insider sale by a top legal executive, executed under a 10b5-1 plan but still carrying a negative sentiment. The aggregate data shows no period-over-period trends, forward guidance, or capital allocation changes, making the Apple sale the only actionable signal. The portfolio-level insight is that blue-chip insider activity is currently dominated by compensation mechanics, with one notable instance of high-value share liquidation.

15 high priority 1 medium 16 total filings
· daily

US Corporate Distress Financial Stress SEC Filings — September 24, 2026

The single filing in this digest, from Beasley Broadcast Group Inc., presents a governance-related distress signal rather than a financial or operational crisis. The death of independent director Peter A. Bordes, Jr. has reduced the Audit Committee to two members, triggering non-compliance with Nasdaq's audit committee independence rule. While this is a procedural issue with a cure period extending to September 2027, it introduces near-term uncertainty regarding board composition and regulatory standing. The event is isolated and does not reflect broader sector-wide distress, but it does highlight governance fragility in a small-cap media company. No period-over-period financial trends, insider trading, capital allocation changes, or forward-looking guidance were available in this filing, limiting the depth of quantitative synthesis. The primary actionable insight is the need to monitor the company's ability to appoint a qualified independent director within the cure period, as failure could lead to delisting risk.

1 high priority 1 total filings
· daily

Global High-Priority Regulatory Events — September 24, 2026

This intelligence digest covers 28 filings from September 24, 2026, dominated by corporate restructuring events (insolvencies, mergers, and delistings) across US and Indian markets. A clear theme is the acceleration of capital recycling through SPAC mergers (Black Hawk, Haymaker V, Live Oak VI, UY Scuti) and tender offers (Utah Medical, Ares Strategic, Beacon Topco, Vista Credit, Evanston Multi-Alpha), with aggregate capital deployment exceeding $500 million. The Indian insolvency landscape shows active resolution plan implementation (Rajeswari Infrastructure, Zicom Electronic Security, Jatalia Global Ventures) with significant shareholder dilution and capital restructuring. Delisting activity is elevated, with three Nasdaq delistings (Jasper Therapeutics, Waldencast, KLX Energy) and one voluntary NYSE delisting (Two Harbors Investment) on the same day, signaling potential distress or strategic repositioning. The banking sector shows consolidation momentum with First Bancorp's acquisition of First Carolina Bancshares valued at ~$1,228 per share. Insider activity is notably absent across most filings, with only Utah Medical's insider group owning 7.9% of shares in a tender offer, providing limited management conviction signals. Forward-looking data points to a catalyst-rich October 2026 with multiple shareholder meetings, open offer deadlines, and merger completion timelines.

28 high priority 28 total filings
· daily

US SEC Filings Daily Market Digest — September 24, 2026

Today's digest reveals a market bifurcated between aggressive capital deployment (M&A, buybacks, debt raises) and operational stress. Key themes include a surge in SPAC activity with three major business combinations progressing (Forge Nano, Mobilewalla, InoBat), signaling renewed appetite for high-growth tech and energy transition plays. However, this is contrasted by significant distress signals: Key Tronic's dramatic loss widening, AMC's balance sheet restructuring, and Starbucks' store closure plan. Period-over-period data shows a mixed earnings picture, with BlackBerry and INLIF posting strong revenue growth (26% YoY each) while Darden and AtlasClear face margin compression. Capital allocation is a dominant theme, with Mizuho and News Corp aggressively buying back shares, and First Merchants issuing subordinated debt for repurchases. Insider activity is limited but notable, with ASE Technology director exercising $29.6M in options, a potential bullish signal. The overall picture is one of strategic repositioning across sectors, with companies either doubling down on growth or shoring up balance sheets.

19 high priority 31 medium 50 total filings
· daily

S&P 500 Consumer Discretionary Sector SEC Filings — September 24, 2026

The four filings in this S&P 500 Consumer Discretionary digest reveal a sector bifurcating between aggressive restructuring and strategic financial positioning. Starbucks' 'Back to Starbucks' plan, involving ~180 store closures and a 27-32% cut to net new store guidance, signals a painful but necessary operational reset in North America, while international expansion remains a growth lever. Marriott's proactive refinancing of its credit facility to $5.0 billion with extended maturity underscores a defensive liquidity play, likely anticipating a slower travel demand environment. At Ford, a director's routine gifting of Class B stock is a neutral signal, but the concentrated insider holdings warrant monitoring for any shift to open-market sales. The withdrawal of IAC's (People Inc.) non-binding bid for MGM Resorts removes a near-term M&A catalyst, but the 26.5% stake holder remains open to strategic alternatives, keeping a long-term premium possibility alive. Across the group, capital discipline (Marriott), operational streamlining (Starbucks), and strategic optionality (MGM) are the dominant themes, with no clear sector-wide growth acceleration evident from the period-over-period data available.

3 high priority 1 medium 4 total filings
· daily

S&P 500 Healthcare Sector SEC Filings — September 24, 2026

The 17 filings for the S&P 500 Healthcare sector on this date are dominated by routine insider equity awards at UnitedHealth Group (10 filings) and a single insider sale at Stryker Corp, alongside a material corporate action filing from Medtronic regarding its diabetes business spin-off. The UnitedHealth awards are uniformly neutral, small in size, and represent standard director/officer compensation, signaling no unusual insider sentiment. The Stryker CFO's disposal of 1,777 shares is a modest but notable insider sale that warrants monitoring. The high-impact event is Medtronic's Rule 425 filing detailing the exchange offer for up to 225 million shares of its newly formed MiniMed diabetes unit, marking a significant step in a major corporate separation. Overall, the digest points to a quiet period for routine insider activity at a mega-cap insurer, a minor insider de-risking at a med-tech leader, and a major catalyst unfolding at Medtronic. No period-over-period financial trends or forward-looking guidance were present in these specific filings, limiting broader sector trend analysis.

17 high priority 17 total filings
· daily

US Earnings Financial Results SEC Filings — September 24, 2026

The 17 filings reveal a bifurcated market. Growth is being driven by cyclical recoveries (BlackBerry, Fuller, Paychex) and one-off events (AtlasClear's stock locate fees), but underlying profitability is under pressure from rising costs (Key Tronic, Campbell's) and margin compression (Trio-Tech, Stitch Fix). Small-cap balance sheets are deteriorating (Legacy Education, Shuttle Pharma, shell companies), while larger names are returning capital via buybacks (BlackBerry, Paychex). Key risks include regulatory threats in education (Legacy Education) and the sustainability of non-core revenue (AtlasClear). Opportunities lie in turnarounds (Stitch Fix, Key Tronic adjusted), M&A-driven re-ratings (Shuttle Pharma), and high-growth niches (BlackBerry, Paychex).

17 high priority 17 total filings
· daily

US Executive Compensation Proxy SEC Filings — September 24, 2026

The 13 pre-analyzed proxy filings for the 2026 annual meeting season reveal a bifurcated landscape: while most companies are conducting routine governance (director elections, auditor ratification, say-on-pay), a significant minority are in crisis or transformation mode, using shareholder meetings to approve fundamental structural changes. The most material developments cluster around three themes: (1) survival-driven reverse stock splits at ESS Tech (1-for-8 to 1-for-30) and KALA BIO (1-for-2 to 1-for-300), signaling acute capital structure distress; (2) M&A liquidity events at Senti Biosciences (fairness-opinioned merger with CVR distribution) and Nathan's Famous (merger with board and insider voting agreements), offering near-term cash exits; and (3) a high-stakes SPAC de-SPAC at Archimedes Tech SPAC Partners II (merging with Forge Nano, $238M in gross proceeds). Period-over-period comparisons from the enriched data show Coty Inc. as the standout turnaround story, reducing net debt by ~$840M YoY while completing its Wella monetization, though still under sales and margin pressure. Insider activity is concentrated in the M&A filings, where directors and officers have locked in voting agreements, signaling conviction in the deal outcomes. Capital allocation is minimal across the set—no dividends or buybacks are highlighted—reflecting a focus on survival and restructuring over shareholder returns. The portfolio-level pattern is clear: routine governance dominates the large-cap filers (ADP, Lam Research, Eaton Vance), while the small- and micro-cap filers (ESS Tech, KALA BIO, Senti, Archimedes, Nathan's) are driving the actionable intelligence for event-driven investors.

13 high priority 13 total filings
· daily

US IPO Pipeline SEC S-1 Filings — September 24, 2026

The IPO pipeline is active with three new filings this week, spanning a REIT merger, a life sciences SPAC, and a clinical-stage biotech IPO, alongside a previously covered bank acquisition. The most material development is City Therapeutics' IPO filing, which reveals a stark contrast between surging collaboration revenue (up 128% YoY) and rapidly widening net losses (from $27.8M to $58.5M in 2025), driven by a 90% surge in R&D spending—a classic high-risk, high-reward biotech profile. The Independence Realty Trust/CSR merger S-4 highlights a fixed-exchange-ratio structure that exposes CSR shareholders to market risk, with a hard deadline of June 30, 2027. The Frazier Life Sciences SPAC IPO is a standard blank-check offering with $75M in trust, while the First Bancorp acquisition of First Carolina Bancshares shows a positive sentiment with a detailed stock-and-cash consideration structure. A key portfolio-level pattern is the divergence in capital intensity: biotech is burning cash aggressively for growth, while financial and REIT sectors are pursuing consolidation with defined deal mechanics.

4 high priority 4 total filings
· daily

US SEC Trading Suspension Halt Orders — September 24, 2026

The single filing in this digest for the USA Trading Suspensions stream relates to Beasley Broadcast Group Inc., which disclosed a governance non-compliance event following the passing of independent director Peter A. Bordes, Jr. This event reduced the Audit Committee to two members, triggering a violation of Nasdaq Rule 5605(c)(2)(A) which requires a minimum of three independent audit committee members. While not a financial performance event, this governance lapse carries a materiality score of 6/10 and a negative sentiment, as it introduces regulatory risk and potential reputational damage. The company has a cure period until the earlier of its next annual meeting or September 19, 2027, to restore compliance, providing a long runway but creating a monitoring situation. No period-over-period comparisons, insider activity, forward-looking guidance, or capital allocation data were available in the enriched data to derive broader trends. The key theme is a single-company governance risk event with a defined remediation timeline, which could lead to a trading suspension or delisting if not resolved, though the risk is currently low given the extended cure period.

1 high priority 1 total filings
· daily

US Executive Officer Management Changes SEC — September 24, 2026

This digest of 26 filings reveals a period of significant leadership transition across multiple sectors, with notable C-suite departures and board refreshments. While most changes are routine governance updates, several high-materiality events stand out, including the rejection of key governance proposals at AMC Entertainment (materiality 8/10) and a key executive departure at Digital Turbine (materiality 5/10). A clear pattern of insider equity acceleration and new grants at GameSquare Holdings (materiality 5/10) suggests management alignment efforts. The appointment of a new CFO at EOG Resources (materiality 4/10) and a new CRO at Zscaler (materiality 5/10) signal strategic succession planning in the energy and cybersecurity sectors. Overall, the filings indicate a healthy level of board refreshment and executive transitions, with shareholder dissent at AMC and America's CarMart highlighting governance concerns. No period-over-period financial comparisons were available in these filings, limiting trend analysis.

26 high priority 26 total filings
· daily

US Corporate Board Director Changes SEC Filings — September 24, 2026

The 26 filings reveal a period of significant board refreshment and executive transition across US equities, with 14 newly published filings showing a high volume of director appointments (7) and C-suite changes (5). While most changes are routine governance updates, several carry material signals: AMC Entertainment's annual meeting saw four governance proposals fail despite overwhelming shareholder support, indicating a structural governance risk. Notable insider activity includes accelerated equity vesting at GameSquare Holdings and a substantial stock bonus at Beam Global, suggesting management retention efforts. Sector themes are emerging, with technology companies (Nutanix, Zscaler, Digital Turbine) experiencing senior leadership departures, while financial services firms (PCB Bancorp, Capitol Federal) are locking in long-term CEO agreements. The overall sentiment is neutral, with isolated pockets of concern at AMC (mixed sentiment, materiality 8/10) and opportunity at Clover Health (positive sentiment, materiality 5/10) due to strategic board appointments.

26 high priority 26 total filings
· daily

USA Insider Trading Pulse — September 24, 2026

The September 24, 2026, insider trading pulse reveals a day dominated by high-value, pre-planned insider selling at the C-suite level, particularly in the technology and healthcare sectors. Notable disposals include SpaceX's President Gwynne Shotwell ($23.4M), Tempus AI's CEO Eric Lefkofsky ($6.1M), and Royalty Pharma's EVP Christopher Hite ($5.6M), all executed under Rule 10b5-1 plans, suggesting portfolio diversification rather than panic. However, a stark contrast emerges with significant insider buying from major institutional holders: Nippon Life Insurance increased its stake in Corebridge Financial by $10.2M, and a director at Advanced Flower Capital added $92.6K, signaling strong conviction in these financial and cannabis-related assets. The data shows a bifurcated market where insiders at high-growth, volatile names are taking profits, while deep-value and financial sector insiders are deploying capital. A cluster of routine director stock awards at UnitedHealth Group (12 filings) and Precision Optics (3 filings) indicates standard compensation practices, providing no directional signal. The most actionable intelligence lies in the divergence between the large-scale selling at SpaceX and Tempus AI and the bullish accumulation in Corebridge Financial and Advanced Flower Capital.

49 high priority 1 medium 50 total filings
· daily

US Merger & Acquisition SEC Filings — September 24, 2026

The US SPAC market is experiencing a surge in activity with three major capital raises and one key merger amendment this week. Black Hawk Acquisition Corp secured a complex $200M+ financing package for its Vesicor Therapeutics combination, though at a high cost with a 15% discount on prepaid advances. Haymaker Acquisition Corp V completed a $295.5M IPO and private placement, signaling strong investor appetite for new SPACs. Live Oak Acquisition Corp VI priced a $200M IPO, adding to the $495.5M in fresh SPAC capital raised this period. UY Scuti Acquisition Corp amended its merger with Isdera Group, setting a $920M valuation and adjusting conversion terms. Columbus Acquisition Corp and ARC Group Securities Acquisition I filed procedural updates with no financial impact. The dominant theme is the continued flow of SPAC capital formation and deal financing, with a notable shift toward costly but necessary financing structures to close pending business combinations.

6 high priority 6 total filings
· monthly

US Pre-Market SEC Filings Roundup — September 24, 2026

The overnight filing period from September 23-24, 2026, presents a complex picture for the US market, dominated by significant corporate actions and mixed financial results. A key theme is aggressive capital management, with major buyback announcements from Mizuho Financial Group and a substantial tender offer from Utah Medical Products, alongside a large secondary offering from InnovAge Holdings. The period also features transformative M&A, including a merger between Afya and Yduqs in Brazilian education and a SPAC combination for Elroy Air, alongside a major debt refinancing by AMC Entertainment. Financially, the picture is bifurcated: AtlasClear Holdings reported explosive revenue growth but deteriorating profitability, while Key Tronic Corp posted a dramatic loss. Insider activity was mixed, with notable purchases in DeFi Development Corp and CapsoVision, countered by significant sales at GigaCloud Technology and Bullish. The most actionable signals point to opportunities in capital return stories and risks in companies with widening losses and shareholder dilution.

28 high priority 22 medium 50 total filings
· daily

Biotech Small-Cap Approvals — September 23, 2026

The September 23, 2026, digest covers three approvals, all classified as 'Other' (FALLBACK type), with zero NMEs, biosimilars, or label expansions. The mix is dominated by two generic/biosimilar entries (CALCIUM GLUCONATE from CIPLA and CYCLOSPORINE from AUROBINDO PHARMA LTD) and one label expansion for EMPAGLIFLOZIN from RIDHISIDHI, PLLC. No dominant therapeutic area theme emerges, as the drugs target distinct mechanisms (SGLT2 inhibition, electrolyte replacement, immunosuppression). The highest-conviction signal is the bullish label expansion for EMPAGLIFLOZIN, though its commercial materiality is limited by a lack of disclosed peak sales and exclusivity data. The key risk is the absence of high-value NME or breakthrough therapy approvals, indicating a low-catalyst period for small-cap biotech investors.

3 total filings
· daily

Big Pharma Approvals — September 23, 2026

During the period of September 23, 2026, two label expansion approvals were granted, both classified as 'Other' with no NMEs, biosimilars, or standard label expansions. The approvals were for abemaciclib (Verzenio) by Eli Lilly and finerenone (Kerendia) by Bayer, both in the cardiovascular/oncology space, signaling continued lifecycle management in these therapeutic areas. Both approvals carry a bullish signal with moderate strength and materiality, indicating incremental commercial value rather than transformative shifts. The highest-conviction signal is the label expansion for finerenone, which strengthens Bayer's position in chronic kidney disease and heart failure, potentially expanding its addressable patient population. Key watch items include the specific indications added and any competitive responses from other CDK4/6 inhibitors or mineralocorticoid receptor antagonists.

2 total filings
· daily

Orphan Drug Approvals — September 23, 2026

This digest covers a single approval on September 23, 2026, comprising zero NMEs, zero biosimilars, zero label expansions, and one 'Other' approval type. The sole event is a label expansion for LEVACETYLLEUCINE (AQNEURSA) by INTRABIO, classified as a FALLBACK approval with a bullish signal. With no NMEs or biosimilars, the period lacks the high-value catalysts or competitive disruption events that typically drive sector-wide moves. The key signal is INTRABIO's ability to secure a label expansion for an orphan drug, though the lack of disclosed commercial data (peak sales, pricing, market position) limits conviction. The primary risk is the absence of any NME or biosimilar activity, which may indicate a quiet period for pipeline catalysts.

1 total filings